Transmitted drug resistance to Tenofovir/Emtricitabine among persons with newly diagnosed HIV infection in Shenyang city, Northeast China from 2016 to 2018.
Abstract: The TDF/FTC DRMs included K65R (8/13), M184I/V (5/13), and Y115F (2/13).
Introduc
Introduction: The main drug resistance mutations (DRMs) to TDF/FTC include K65R and M184I/V, but the global incidence was rather low in HIV ART-naive patients.
Result: K65R is known to confer high-level resistance to TDF and intermediate-level resistance to FTC, while M184I/V confers high-level resistance to FTC and 3TC and low-level resistance to abacavir (ABC).
Result: The mutations included K65R (61.5%, 8/13), M184I/V (38.5%, 5/13), and Y115F (2/13).
Table: M184I
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 33734374
2021
The Journal of antimicrobial chemotherapy
Abstract: In December 2019, the remaining three subjects carrying M184V/I in pDNA maintained suppressed viraemia, and two still used emtricitabine in ART.
Abstract: METHODS: We included vertically HIV-infected youths/young adults aged >=10 years in the Madrid Cohort of HIV-1 Infected Children and Adolescents, exposed to lamivudine and/or emtricitabine, with M184V/I and/or K65R/E/N in historic plasma samples, on antiretroviral therapy (ART), virologically suppressed (HIV-1 RNA <50 copies/mL), and with available PBMCs in the Spanish HIV BioBank.
Abstract: Nine (75%) youths did not present M184V/I in pDNA after at least 1 year of viral suppression.
Abstract: OBJECTIVES: We analysed the prevalence of M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 33722682
2021
International journal of infectious diseases
Abstract: DISCUSSION: Despite high prevalence of M184V/I in antiretroviral therapy (ART) experienced patients, DTG treatment outcomes will likely not be adversely affected by this mutation.
Abstract: DTG-based regimens have to great extent been effective at maintaining viral suppression in treatment experienced PLWH carrying M184V/I.
Abstract: High genetic barrier to the development of resistance associated with DTG and progressive viral suppression in patients switched to DTG-based therapy with M184V/I, may encourage better DTG outcomes and help in curbing increasing levels of HIV drug resistance in LMICs.
Abstract: Lamivudine and emtricitabine associated M184V/I mutation is highly prevalent in PLWH and the majority of HIV infected individuals receiving DTG regimen
HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China.
Abstract: In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies.
Result: Although these variants still existed at follow-up, the frequencies of the mutations M184VI, K103N and P225H decreased over time, and most of them remained at frequencies of more than 20%.
Result: At baseline, mutations with a frequency of 20% and above were NRTI-related, such as M184VI (2.0%, 1/49), and NNRTI-related like K103N (14.3%, 7/49), E138AG (4.1%, 2/49),
Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation.
Abstract: Certain Apolipoprotein B Editing Complex 3-related DRMs including reverse transcriptase gene mutations M184I, E138K, M230I, G190E and protease gene mutations M46I, D30N were enriched in hypermutated sequences but not in intact sequences or plasma sequences.
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 33624081
2021
The Journal of antimicrobial chemotherapy
Abstract: OBJECTIVES: We aimed to deep analyse the detection of M184V/I variants at time of switch and at the time of virological failure (VF).
Abstract: The 48 week estimated probability of remaining free from VF was comparable with or without the M184V/I mutation for dual therapy.
Abstract: The proportion of M184V/I variants was described and the association between the M184V/I mutation at 1% of threshold and VF was explored with logistic regression models.
Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).
PMID: 33624081
2021
The Journal of antimicrobial chemotherapy
Abstract: M184I mutation was always associated with a STOP codon, suggesting defective virus.
Increase in HIV-1-transmitted drug resistance among ART-naive youths at the China-Myanmar border during 2009 ~ 2017.
Result: Among NRTIs, except M184I (1), L74I (1), D67N (1), and T215I (1), the remaining mutations (75%, 12/16) only conferred potential resistance (score < 15) to NRTIs.
Table: M184I
Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan.
PMID: 32873061
2021
AIDS research and human retroviruses
Abstract: In ART-experienced patients, cohort II, 77.4% (82/106) of viruses contained at least one mutation against PIs, NRTIs, or NNRTIs, with the most common mutations of M184V/I (49.1%; 52/106), K65R (18.9%; 20/106), K103N (23.6%; 25/106), and G190S (22.6%; 24/106).
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
PMID: 33200210
2021
The Journal of antimicrobial chemotherapy
Abstract: Baseline proviral DNA NGS detected lamivudine RAMs (M184V/I and/or K65R/E/N) above a 5% threshold in 71.4% (15/21) and 15% (3/20) of participants with and without history of lamivudine resistance, respectively.
HIV mutation literature information.
PMID: 
2021
BMC infectious diseases
Browser Board
Co-occurred Entities
Filtrator
ViMRT